<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8050264</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">33859210</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">8050264</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">87088</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1038/s41598-021-87088-z</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical data of subjects.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical data of subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Sex</th><th align="left">Age</th><th align="left">Total BoNT-A dose (Botox)</th><th align="left">TWSTRS at Week 0</th><th align="left">TWSTRS at Week 4</th></tr></thead><tbody><tr><td align="left">F</td><td align="left">39</td><td align="left">150</td><td align="left">15</td><td align="left">6</td></tr><tr><td align="left">F</td><td align="left">55</td><td align="left">200</td><td align="left">11</td><td align="left">5</td></tr><tr><td align="left">F</td><td align="left">38</td><td align="left">100</td><td align="left">12</td><td align="left">4</td></tr><tr><td align="left">F</td><td align="left">50</td><td align="left">200</td><td align="left">16</td><td align="left">6</td></tr><tr><td align="left">F</td><td align="left">47</td><td align="left">200</td><td align="left">16</td><td align="left">6</td></tr><tr><td align="left">M</td><td align="left">49</td><td align="left">150</td><td align="left">12</td><td align="left">6</td></tr><tr><td align="left">F</td><td align="left">61</td><td align="left">150</td><td align="left">13</td><td align="left">10</td></tr><tr><td align="left">F</td><td align="left">49</td><td align="left">125</td><td align="left">14</td><td align="left">12</td></tr><tr><td align="left">F</td><td align="left">60</td><td align="left">200</td><td align="left">21</td><td align="left">13</td></tr><tr><td align="left">F</td><td align="left">60</td><td align="left">200</td><td align="left">18</td><td align="left">13</td></tr><tr><td align="left">F</td><td align="left">44</td><td align="left">200</td><td align="left">13</td><td align="left">13</td></tr><tr><td align="left">F</td><td align="left">58</td><td align="left">200</td><td align="left">10</td><td align="left">5</td></tr><tr><td align="left">F</td><td align="left">63</td><td align="left">175</td><td align="left">13</td><td align="left">12</td></tr><tr><td align="left">M</td><td align="left">43</td><td align="left">100</td><td align="left">17</td><td align="left">11</td></tr><tr><td align="left">F</td><td align="left">40</td><td align="left">125</td><td align="left">14</td><td align="left">9</td></tr><tr><td align="left">F</td><td align="left">56</td><td align="left">175</td><td align="left">18</td><td align="left">10</td></tr><tr><td align="left">M</td><td align="left">41</td><td align="left">100</td><td align="left">10</td><td align="left">7</td></tr><tr><td align="left">Mean</td><td align="left">50.2</td><td align="left">161.8</td><td align="left">14.3</td><td align="left">8.7</td></tr></tbody></table><table-wrap-foot><p>List of 17 subjects with thein sex and age, total dose of BoNT used for single application and score of TWSTRS at W0 and W4. Abbreviations: F—female, M-male.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical data of subjects.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">Sex</th><th align="left">Age</th><th align="left">Total BoNT-A dose (Botox)</th><th align="left">TWSTRS at Week 0</th><th align="left">TWSTRS at Week 4</th></tr></thead><tbody><tr><td align="left">F</td><td align="left">39</td><td align="left">150</td><td align="left">15</td><td align="left">6</td></tr><tr><td align="left">F</td><td align="left">55</td><td align="left">200</td><td align="left">11</td><td align="left">5</td></tr><tr><td align="left">F</td><td align="left">38</td><td align="left">100</td><td align="left">12</td><td align="left">4</td></tr><tr><td align="left">F</td><td align="left">50</td><td align="left">200</td><td align="left">16</td><td align="left">6</td></tr><tr><td align="left">F</td><td align="left">47</td><td align="left">200</td><td align="left">16</td><td align="left">6</td></tr><tr><td align="left">M</td><td align="left">49</td><td align="left">150</td><td align="left">12</td><td align="left">6</td></tr><tr><td align="left">F</td><td align="left">61</td><td align="left">150</td><td align="left">13</td><td align="left">10</td></tr><tr><td align="left">F</td><td align="left">49</td><td align="left">125</td><td align="left">14</td><td align="left">12</td></tr><tr><td align="left">F</td><td align="left">60</td><td align="left">200</td><td align="left">21</td><td align="left">13</td></tr><tr><td align="left">F</td><td align="left">60</td><td align="left">200</td><td align="left">18</td><td align="left">13</td></tr><tr><td align="left">F</td><td align="left">44</td><td align="left">200</td><td align="left">13</td><td align="left">13</td></tr><tr><td align="left">F</td><td align="left">58</td><td align="left">200</td><td align="left">10</td><td align="left">5</td></tr><tr><td align="left">F</td><td align="left">63</td><td align="left">175</td><td align="left">13</td><td align="left">12</td></tr><tr><td align="left">M</td><td align="left">43</td><td align="left">100</td><td align="left">17</td><td align="left">11</td></tr><tr><td align="left">F</td><td align="left">40</td><td align="left">125</td><td align="left">14</td><td align="left">9</td></tr><tr><td align="left">F</td><td align="left">56</td><td align="left">175</td><td align="left">18</td><td align="left">10</td></tr><tr><td align="left">M</td><td align="left">41</td><td align="left">100</td><td align="left">10</td><td align="left">7</td></tr><tr><td align="left">Mean</td><td align="left">50.2</td><td align="left">161.8</td><td align="left">14.3</td><td align="left">8.7</td></tr></tbody></table></div>List of 17 subjects with thein sex and age, total dose of BoNT used for single application and score of TWSTRS at W0 and W4. Abbreviations: F—female, M-male.</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>List of significant clusters in the contrasts PreW0 – &gt; W4, W4 &gt; W0, Post contrast and correlation with TWSTRS change.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2"><label>Table 2</label><caption><p>List of significant clusters in the contrasts PreW0 – &gt; W4, W4 &gt; W0, Post contrast and correlation with TWSTRS change.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Seed</th><th align="left">Contrast</th><th align="left">Cluster Index</th><th align="left">Cluster <italic>P </italic>value</th><th align="left">Volume (cm<sup>3</sup>)</th><th align="left">Z<sub>max</sub></th><th align="left">Z<sub>max</sub> MNI coordinates</th><th align="left">Atlas</th></tr></thead><tbody><tr><td align="left" rowspan="2">Right VI</td><td align="left" rowspan="2">Positive corr</td><td align="left" rowspan="2"><bold>1</bold></td><td align="left" rowspan="2"><bold>8.30E−04</bold></td><td char="." align="char" rowspan="2">4.08</td><td char="." align="char" rowspan="2">3.99</td><td align="left" rowspan="2">18–80–44</td><td align="left">79.8% R CRBL Crus II</td></tr><tr><td align="left">10.0% R CRBL VIIb</td></tr><tr><td align="left" rowspan="6">Right Crus II</td><td align="left" rowspan="6">Positive corr</td><td align="left" rowspan="3"><bold>1</bold></td><td align="left" rowspan="3"><bold>8.24E−05</bold></td><td char="." align="char" rowspan="3">6.11</td><td char="." align="char" rowspan="3">4.20</td><td align="left" rowspan="3">34 56 2</td><td align="left">63.7% R Frontal Pole</td></tr><tr><td align="left">18.6% R Inferior Frontal G, p.t</td></tr><tr><td align="left">12.7% R Inferior Frontal G, p.o</td></tr><tr><td align="left" rowspan="3">2</td><td align="left" rowspan="3">1.34E − -02</td><td char="." align="char" rowspan="3">2.62</td><td char="." align="char" rowspan="3">3.68</td><td align="left" rowspan="3"> − 40 38 8</td><td align="left">70.7% L Frontal Pole</td></tr><tr><td align="left">17.4% L Middle Frontal G</td></tr><tr><td align="left">6.1% L Inferior Frontal G, p.t</td></tr><tr><td align="left" rowspan="2">Vermis VIIIa</td><td align="left" rowspan="2">AW0 &gt; BW4</td><td align="left" rowspan="2">1</td><td align="left" rowspan="2"><bold>6.77E−04</bold></td><td char="." align="char" rowspan="2">3.21</td><td char="." align="char" rowspan="2">3.92</td><td align="left" rowspan="2"> − 12 24 60</td><td align="left">92.3% L Superior Frontal G</td></tr><tr><td align="left">7.7% L Paracingulate G</td></tr><tr><td align="left" rowspan="26">Vermis VIIIb</td><td align="left" rowspan="26">Positive corr</td><td align="left" rowspan="4">1</td><td align="left" rowspan="4"><bold>1.54E−04</bold></td><td char="." align="char" rowspan="4">4.20</td><td char="." align="char" rowspan="4">4.16</td><td align="left" rowspan="4">64−40 8</td><td align="left">31.6% R Supramarginal G, p.d</td></tr><tr><td align="left">28.2% R Middle Temporal G, t-o.p</td></tr><tr><td align="left">22.5% R Middle Temporal G, p.d</td></tr><tr><td align="left">14.9% R Superior Temporal G, p.d</td></tr><tr><td align="left" rowspan="3">2</td><td align="left" rowspan="3"><bold>3.19E−04</bold></td><td char="." align="char" rowspan="3">3.81</td><td char="." align="char" rowspan="3">3.84</td><td align="left" rowspan="3"> −46 24 32</td><td align="left">86.3% L Middle Frontal G</td></tr><tr><td align="left">8.4% L Inferior Frontal G, p.o</td></tr><tr><td align="left">5.0% L Precentral G</td></tr><tr><td align="left" rowspan="3">3</td><td align="left" rowspan="3"><bold>4.46E−04</bold></td><td char="." align="char" rowspan="3">3.63</td><td char="." align="char" rowspan="3">3.96</td><td align="left" rowspan="3">46 2 36</td><td align="left">44.1% R Precentral G</td></tr><tr><td align="left">30.0% R Middle Frontal G</td></tr><tr><td align="left">25.3% R Inferior Frontal G, p.o</td></tr><tr><td align="left" rowspan="4">4</td><td align="left" rowspan="4">1.39E−03</td><td char="." align="char" rowspan="4">3.06</td><td char="." align="char" rowspan="4">4.31</td><td align="left" rowspan="4">34–76−46</td><td align="left">50.5% R CRBL Crus II</td></tr><tr><td align="left">22.5% R CRBL VIIb</td></tr><tr><td align="left">19.4% R CRBL Crus I</td></tr><tr><td align="left">6.5% R CRBL VI</td></tr><tr><td align="left" rowspan="6">5</td><td align="left" rowspan="6">5.39E−03</td><td char="." align="char" rowspan="6">2.42</td><td char="." align="char" rowspan="6">3.84</td><td align="left" rowspan="6"> −6 − 74 −28</td><td align="left">53.6% L CRBL VI</td></tr><tr><td align="left">30.1% CRBL Vermis VI</td></tr><tr><td align="left">22.5% L Lingual G</td></tr><tr><td align="left">8.6% R Lingual G</td></tr><tr><td align="left">6.0% L Occipital Fusiform G</td></tr><tr><td align="left">5.3% L CRBL Crus I</td></tr><tr><td align="left" rowspan="3">6</td><td align="left" rowspan="3">5.39E−03</td><td char="." align="char" rowspan="3">1.74</td><td char="." align="char" rowspan="3">3.56</td><td align="left" rowspan="3">46 22–6</td><td align="left">60.1% R Frontal Pole</td></tr><tr><td align="left">20.6% R Frontal Orbital C</td></tr><tr><td align="left">14.2% R Inferior Frontal G, p.t</td></tr><tr><td align="left" rowspan="3">7</td><td align="left" rowspan="3">3.09E−02</td><td char="." align="char" rowspan="3">1.66</td><td char="." align="char" rowspan="3">3.75</td><td align="left" rowspan="3"> −56–48 4</td><td align="left">46.2% L Middle Temporal G, t-o.p</td></tr><tr><td align="left">34.1% L Planum Temporale</td></tr><tr><td align="left">16.8% L Superior Temporal G, p.d</td></tr><tr><td align="left" rowspan="2">Right IX</td><td align="left" rowspan="2">Positive corr</td><td align="left">1</td><td align="left"><bold>6.57E−04</bold></td><td char="." align="char">4.16</td><td char="." align="char">4.13</td><td align="left"> −26–76 −48</td><td align="left"><p>32.5% L CRBL Crus II</p><p>31.5% L CRBL Crus I</p><p>20.6% L CRBL VI</p><p>15.4% L CRBL VIIb</p></td></tr><tr><td align="left">2</td><td align="left">4.76E−02</td><td char="." align="char">1.76</td><td char="." align="char">4.06</td><td align="left">8−34–42</td><td align="left">100% Brain-Stem</td></tr></tbody></table><table-wrap-foot><p>Table lists significant t-test clusters in the contrast W0 &gt; W4, W4 &gt; W0, positive, and negative correlation (corr.) with TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale) change. Bold indicates clusters significant after Bonferroni correction. Anatomical labels with the highest probability per voxel are provided including the proportion of labeled voxels. Only labels consisting at least 5% of activated voxels are shown. Note that cerebellar labels may overlap with cortical labels. Abbreviations: C, cortex; CRBL, cerebellum; G, gyrus; L, left; MNI, Montréal Neurological Institute; p.d., posterior division; p.o., pars opercularis; p.t., pars triangularis; R, right; t-o.p., temporooccipital part; W0, Week 0; W4, Week 4; Z<sub>max</sub>, maximum Z score.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">List of significant clusters in the contrasts PreW0 – &gt; W4, W4 &gt; W0, Post contrast and correlation with TWSTRS change.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">Seed</th><th align="left">Contrast</th><th align="left">Cluster Index</th><th align="left">Cluster P value</th><th align="left">Volume (cm3)</th><th align="left">Zmax</th><th align="left">Zmax MNI coordinates</th><th align="left">Atlas</th></tr></thead><tbody><tr><td align="left" rowspan="2">Right VI</td><td align="left" rowspan="2">Positive corr</td><td align="left" rowspan="2">1</td><td align="left" rowspan="2">8.30E−04</td><td char="." align="char" rowspan="2">4.08</td><td char="." align="char" rowspan="2">3.99</td><td align="left" rowspan="2">18–80–44</td><td align="left">79.8% R CRBL Crus II</td></tr><tr><td align="left">10.0% R CRBL VIIb</td></tr><tr><td align="left" rowspan="6">Right Crus II</td><td align="left" rowspan="6">Positive corr</td><td align="left" rowspan="3">1</td><td align="left" rowspan="3">8.24E−05</td><td char="." align="char" rowspan="3">6.11</td><td char="." align="char" rowspan="3">4.20</td><td align="left" rowspan="3">34 56 2</td><td align="left">63.7% R Frontal Pole</td></tr><tr><td align="left">18.6% R Inferior Frontal G, p.t</td></tr><tr><td align="left">12.7% R Inferior Frontal G, p.o</td></tr><tr><td align="left" rowspan="3">2</td><td align="left" rowspan="3">1.34E − -02</td><td char="." align="char" rowspan="3">2.62</td><td char="." align="char" rowspan="3">3.68</td><td align="left" rowspan="3"> − 40 38 8</td><td align="left">70.7% L Frontal Pole</td></tr><tr><td align="left">17.4% L Middle Frontal G</td></tr><tr><td align="left">6.1% L Inferior Frontal G, p.t</td></tr><tr><td align="left" rowspan="2">Vermis VIIIa</td><td align="left" rowspan="2">AW0 &gt; BW4</td><td align="left" rowspan="2">1</td><td align="left" rowspan="2">6.77E−04</td><td char="." align="char" rowspan="2">3.21</td><td char="." align="char" rowspan="2">3.92</td><td align="left" rowspan="2"> − 12 24 60</td><td align="left">92.3% L Superior Frontal G</td></tr><tr><td align="left">7.7% L Paracingulate G</td></tr><tr><td align="left" rowspan="26">Vermis VIIIb</td><td align="left" rowspan="26">Positive corr</td><td align="left" rowspan="4">1</td><td align="left" rowspan="4">1.54E−04</td><td char="." align="char" rowspan="4">4.20</td><td char="." align="char" rowspan="4">4.16</td><td align="left" rowspan="4">64−40 8</td><td align="left">31.6% R Supramarginal G, p.d</td></tr><tr><td align="left">28.2% R Middle Temporal G, t-o.p</td></tr><tr><td align="left">22.5% R Middle Temporal G, p.d</td></tr><tr><td align="left">14.9% R Superior Temporal G, p.d</td></tr><tr><td align="left" rowspan="3">2</td><td align="left" rowspan="3">3.19E−04</td><td char="." align="char" rowspan="3">3.81</td><td char="." align="char" rowspan="3">3.84</td><td align="left" rowspan="3"> −46 24 32</td><td align="left">86.3% L Middle Frontal G</td></tr><tr><td align="left">8.4% L Inferior Frontal G, p.o</td></tr><tr><td align="left">5.0% L Precentral G</td></tr><tr><td align="left" rowspan="3">3</td><td align="left" rowspan="3">4.46E−04</td><td char="." align="char" rowspan="3">3.63</td><td char="." align="char" rowspan="3">3.96</td><td align="left" rowspan="3">46 2 36</td><td align="left">44.1% R Precentral G</td></tr><tr><td align="left">30.0% R Middle Frontal G</td></tr><tr><td align="left">25.3% R Inferior Frontal G, p.o</td></tr><tr><td align="left" rowspan="4">4</td><td align="left" rowspan="4">1.39E−03</td><td char="." align="char" rowspan="4">3.06</td><td char="." align="char" rowspan="4">4.31</td><td align="left" rowspan="4">34–76−46</td><td align="left">50.5% R CRBL Crus II</td></tr><tr><td align="left">22.5% R CRBL VIIb</td></tr><tr><td align="left">19.4% R CRBL Crus I</td></tr><tr><td align="left">6.5% R CRBL VI</td></tr><tr><td align="left" rowspan="6">5</td><td align="left" rowspan="6">5.39E−03</td><td char="." align="char" rowspan="6">2.42</td><td char="." align="char" rowspan="6">3.84</td><td align="left" rowspan="6"> −6 − 74 −28</td><td align="left">53.6% L CRBL VI</td></tr><tr><td align="left">30.1% CRBL Vermis VI</td></tr><tr><td align="left">22.5% L Lingual G</td></tr><tr><td align="left">8.6% R Lingual G</td></tr><tr><td align="left">6.0% L Occipital Fusiform G</td></tr><tr><td align="left">5.3% L CRBL Crus I</td></tr><tr><td align="left" rowspan="3">6</td><td align="left" rowspan="3">5.39E−03</td><td char="." align="char" rowspan="3">1.74</td><td char="." align="char" rowspan="3">3.56</td><td align="left" rowspan="3">46 22–6</td><td align="left">60.1% R Frontal Pole</td></tr><tr><td align="left">20.6% R Frontal Orbital C</td></tr><tr><td align="left">14.2% R Inferior Frontal G, p.t</td></tr><tr><td align="left" rowspan="3">7</td><td align="left" rowspan="3">3.09E−02</td><td char="." align="char" rowspan="3">1.66</td><td char="." align="char" rowspan="3">3.75</td><td align="left" rowspan="3"> −56–48 4</td><td align="left">46.2% L Middle Temporal G, t-o.p</td></tr><tr><td align="left">34.1% L Planum Temporale</td></tr><tr><td align="left">16.8% L Superior Temporal G, p.d</td></tr><tr><td align="left" rowspan="2">Right IX</td><td align="left" rowspan="2">Positive corr</td><td align="left">1</td><td align="left">6.57E−04</td><td char="." align="char">4.16</td><td char="." align="char">4.13</td><td align="left"> −26–76 −48</td><td align="left">32.5% L CRBL Crus II31.5% L CRBL Crus I20.6% L CRBL VI15.4% L CRBL VIIb</td></tr><tr><td align="left">2</td><td align="left">4.76E−02</td><td char="." align="char">1.76</td><td char="." align="char">4.06</td><td align="left">8−34–42</td><td align="left">100% Brain-Stem</td></tr></tbody></table></div>Table lists significant t-test clusters in the contrast W0 &gt; W4, W4 &gt; W0, positive, and negative correlation (corr.) with TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale) change. Bold indicates clusters significant after Bonferroni correction. Anatomical labels with the highest probability per voxel are provided including the proportion of labeled voxels. Only labels consisting at least 5% of activated voxels are shown. Note that cerebellar labels may overlap with cortical labels. Abbreviations: C, cortex; CRBL, cerebellum; G, gyrus; L, left; MNI, Montréal Neurological Institute; p.d., posterior division; p.o., pars opercularis; p.t., pars triangularis; R, right; t-o.p., temporooccipital part; W0, Week 0; W4, Week 4; Zmax, maximum Z score.</transformed-table></extracted-table></extracted-tables-set>